An Emergency Medicine Broadsheet
·Phoenix·
Est. MMXXVI
Blue Fish Med · Today's Topic
Adverse Effects of Immune Checkpoint Inhibitors
Immune checkpoint inhibitors can inflame almost any organ, and severe toxicity may progress quickly despite initially nonspecific symptoms. Missing myocarditis, pneumonitis, colitis, or adrenal crisis can be fatal; reflexively giving immunosuppression without considering infection can also harm.
Also known asimmune-related adverse events · irAEs · checkpoint inhibitor toxicity · immunotherapy toxicity
A 62-year-old woman with melanoma sits forward on the stretcher, too tired to finish a sentence. Her skin is cool, her mouth dry, and she says even water makes her nauseated. She received her latest infusion nine days ago; the monitor shows a blood pressure of 82/50. The team is deciding what to draw—and what cannot wait.
— What’s your move? Read on.
Before you read
When should treatment begin before confirmatory testing returns?
Which early clues point to endocrine toxicity rather than infection?
When to Think of It
Consider an immune-related adverse event (irAE) in anyone taking or recently treated with a checkpoint inhibitor who develops new dyspnea, chest pain, diarrhea, abdominal pain, weakness, confusion, rash, or unexplained organ dysfunction. Toxicity can arise weeks to months after treatment—or after it has stopped.
Sick or Not Sick
The key fork is stable, mild symptoms versus organ-threatening disease or physiologic instability. Shock, hypoxia, chest pain, new arrhythmia, altered mental status, severe diarrhea, or rapidly worsening organ function means treat as severe while investigating competing causes.
The First Fifteen Minutes
If hypotensive with suspected adrenal crisis: draw cortisol and ACTH first if this causes no delay, then give hydrocortisone 100 mg IV; it replaces deficient cortisol and restores vascular responsiveness. Give 1 L isotonic crystalloid IV, then reassess perfusion and repeat as indicated.
If severe or rapidly progressive irAE is suspected: give methylprednisolone 1–2 mg/kg IV; suppressing immune-mediated inflammation may limit organ injury. For suspected ICI myocarditis with instability or significant cardiac injury, give methylprednisolone 1,000 mg IV daily and involve cardiology/oncology emergently.
If hypoglycemic: give dextrose 25 g IV (e.g., D50W 50 mL); it rapidly corrects neuroglycopenia while the cause is addressed.
Obtain ECG and troponin for possible myocarditis; assess oxygenation and chest imaging for pneumonitis; check electrolytes, glucose, renal/liver function, and stool studies when indicated. Do not let testing delay resuscitation.
Definitive Care & Disposition
Hold further checkpoint inhibitor doses during suspected clinically significant toxicity and contact oncology early. Admit severe or organ-threatening cases; use ICU care for shock, respiratory failure, significant arrhythmia, or rapidly evolving myocarditis. Tailor investigations to the affected organ and exclude infection, tumor progression, and other medication effects. Endocrine deficiencies may require long-term hormone replacement; persistent severe inflammation may need specialist-directed additional immunomodulation.
How This One Kills
Treating unexplained fatigue, nausea, and hypotension as routine dehydration can miss adrenal crisis; waiting for a cortisol result before giving glucocorticoid can turn a reversible emergency into refractory shock.
The Differential — What Else Looks Like This
Sepsis — fever, cultures, or a plausible source may support it, but infection and irAE can coexist; assuming only inflammation may delay antibiotics.
Tumor progression — imaging may show disease at the affected organ; mislabeling progression as toxicity can lead to harmful immunosuppression.
Acute coronary syndrome — ischemic ECG changes or a regional wall-motion pattern favor it; missing ICI myocarditis risks sudden arrhythmia or death.
Infectious colitis — stool pathogen testing may identify a cause; treating infection as immune colitis can worsen it.
The Second-Day Story
In older adults, symptoms may be limited to falls, confusion, poor intake, or a subtle rise in creatinine; after steroids or antipyretics, fever and inflammatory signs may be muted. Toxicity may also emerge well after the last infusion. Reconcile the immunotherapy history, compare with baseline function and laboratory values, and screen the organ systems suggested by the presentation rather than relying on a classic syndrome.
Back to Our Patient
Back to our 62-year-old with cool skin, nausea, and a blood pressure of 82/50: her recent checkpoint inhibitor exposure makes an irAE a bedside consideration, but shock is the call that matters most. Draw cortisol and ACTH if immediately feasible, give hydrocortisone 100 mg IV and isotonic fluid, and check glucose, electrolytes, ECG, and troponin while evaluating for infection and other causes. Her sodium is low, glucose is 58 mg/dL, and cortisol is profoundly low; she improves with resuscitation and is admitted for adrenal-crisis management and evaluation for treatment-related endocrine toxicity.
Patient Presentation to Attending
How you’d present this patient on the floor — tight, pertinent positives and negatives, no rambling
“This is a 62-year-old woman with melanoma on recent checkpoint inhibitor therapy, presenting with profound fatigue, nausea, and hypotension. She received her last infusion nine days ago and has had poor intake, but no fever, diarrhea, chest pain, dyspnea, or focal infectious symptoms. She is cool and dry, with a blood pressure of 82/50 and no respiratory distress. Glucose is 58, sodium is low, and her cortisol is profoundly low; ECG and initial troponin do not suggest myocarditis. I’m concerned for immune therapy–associated adrenal crisis, while continuing to evaluate for infection and other causes of shock. I’ve drawn endocrine studies without delaying hydrocortisone and fluid resuscitation, and I recommend admission for ongoing treatment and oncology/endocrinology evaluation.”
Study Directive
From memory, list five organ systems affected by checkpoint inhibitors and one emergency presentation for each.
Practice a 60-second approach to suspected adrenal crisis: bedside clues, time-critical labs, and treatment trigger.
Review your institution’s irAE grading and escalation pathway; identify whom to call for suspected myocarditis, pneumonitis, and severe colitis.
Ramos-Casals M, Sisó-Almirall A · Ann Intern Med, 2024 · PMID 38346306 · cited 93×
Recognize checkpoint inhibitor toxicities across organ systems early, and start appropriate evaluation and treatment before inflammation becomes life-threatening.
More in Today's Issue
3 additional topics
2 of 4
Approach to the Solid Organ Transplant Recipient
Transplant recipients may have muted infection signs, unusual pathogens, and organ-specific complications. Delayed sepsis treatment or reflexively stopping...
Also known assolid organ transplant patient · SOT recipient · post-transplant patient · transplant recipient
A 56-year-old kidney-transplant recipient arrives shivering beneath a thin blanket, breathing fast enough to fog the oxygen mask. His partner says he was walking normally yesterday; today he can barely stand. The chart shows a new rise in creatinine, but his usual numbers are not yet in view. The team must decide whether this is an unstable infection, graft dysfunction, or both.
Before You Read
Which bedside finding most changes the first minutes of care?
Why can a “normal” fever history be falsely reassuring?
What should happen to baseline antirejection medicines while the cause is unclear?
Why It Matters
Transplant recipients may have muted infection signs, unusual pathogens, and organ-specific complications. Delayed sepsis treatment or reflexively stopping immunosuppression can threaten both life and graft function.
When to Think of It
Keep transplantation in the differential for fever, hypotension, respiratory or abdominal symptoms, altered mental status, reduced urine output, or a new change in graft function. Establish organ type, transplant date, baseline function, recent rejection treatment, prophylaxis, medication adherence, and recent procedures.
Sick or Not Sick
Is the patient in shock or otherwise unstable? That decision drives immediate resuscitation and empiric antimicrobial therapy; graft rejection, infection, obstruction, medication toxicity, and malignancy can be sorted in parallel.
The First Fifteen Minutes
If hypotension or hypoperfusion is present: give balanced crystalloid up to 30 mL/kg IV, in reassessed boluses; restoring intravascular volume supports perfusion while avoiding unexamined fluid overload.
If shock persists after initial fluid or fluids are unsafe: start norepinephrine 0.05–0.1 mcg/kg/min IV, titrated to perfusion and a usual MAP target of at least 65 mm Hg; it restores vascular tone.
If sepsis is suspected and broad antipseudomonal/MRSA coverage is appropriate: give cefepime 2 g IV and vancomycin 20–25 mg/kg IV loading dose (maximum 3 g); they cover serious gram-negative, including Pseudomonas, and MRSA infection while cultures are pending. Adjust for renal function and local protocols; do not delay indicated antibiotics for imaging or transplant-team callback.
Obtain cultures, lactate, CBC, metabolic panel, urinalysis/culture when relevant, and organ-directed imaging. Contact the transplant center early; avoid contrast or fluid decisions based on graft status alone.
Definitive Care & Disposition
Admit unstable patients and those with suspected serious infection, graft dysfunction, or need for urgent specialty evaluation. Use ICU care for shock or organ failure. Compare renal or hepatic results with the patient’s baseline, assess graft blood flow/obstruction when indicated, and pursue source-directed testing. Do not abruptly stop baseline antirejection therapy without transplant-team input; adjust it with the transplant service once the likely cause and severity are clearer.
How This One Kills
Assuming a transplant recipient cannot be septic because they lack a high fever—or waiting for a transplant specialist before starting indicated sepsis resuscitation—can allow rapid progression to shock and graft injury.
The Atypical Presentation
Immunosuppression may blunt fever, leukocytosis, and local inflammatory signs; older patients may present mainly with weakness, confusion, falls, or a small change from baseline laboratory values. Reconstruct the medication and transplant history, compare with baseline organ function, and treat physiologic instability—not the absence of a textbook fever—as the urgency signal.
Back to Our Patient
Back to our 56-year-old with chills, fast breathing, and a new creatinine rise: his rapid breathing and inability to stand prompt immediate assessment for shock, while the transplant history raises the stakes of both infection and graft dysfunction. He is hypotensive with elevated lactate, so he receives reassessed crystalloid boluses, empiric cefepime and vancomycin with renal dosing review, and norepinephrine when hypotension persists. Cultures are obtained and the transplant center is contacted; he is admitted to the ICU for sepsis management and parallel evaluation of the allograft.
Patient Presentation to Attending
“This is a 56-year-old kidney-transplant recipient with one day of rigors, weakness, and worsening dyspnea, now unable to stand. He was functioning normally yesterday; his partner reports no known missed immunosuppression, and his usual creatinine is not yet confirmed. He is tachypneic and hypotensive with elevated lactate, without a clear source on initial assessment. Creatinine is above the available baseline; cultures are pending. I’m concerned for septic shock in an immunosuppressed patient with possible allograft dysfunction. He has received reassessed crystalloid, broad empiric antibiotics, and norepinephrine for persistent hypotension; I recommend ICU admission and immediate transplant-team involvement.”
Study Directive
Build a one-minute transplant history checklist: organ, date, baseline function, medications, adherence, prophylaxis, and recent rejection therapy.
Review your local sepsis antibiotic options and renal-adjustment pathway; identify how to reach the transplant service overnight.
Practice distinguishing sepsis, rejection, drug toxicity, and obstruction using one case vignette for each.
Key Medications
Cefepime: 2 g IV for initial broad antipseudomonal coverage when indicated; renal-adjust subsequent dosing.
Vancomycin: 20–25 mg/kg IV loading dose, maximum 3 g; subsequent dosing and monitoring depend on renal function, weight, and protocol.
Norepinephrine: start 0.05–0.1 mcg/kg/min IV and titrate to response.
Balanced crystalloid: reassessed boluses, up to 30 mL/kg when indicated for sepsis-associated hypoperfusion.
Doses, especially antimicrobials, require renal adjustment; check institutional guidance or a dosing reference if uncertain. Pediatric transplant dosing is weight-based and specialist/protocol dependent.
High-Yield Pearls
A small creatinine rise may be clinically important; interpret it against the patient’s baseline, not the laboratory reference range alone.
Recent rejection treatment can substantially change infection risk—ask specifically about it.
Early transplant-center consultation helps avoid both inappropriate immunosuppression changes and delays in graft-specific evaluation.
The Mimics
Acute rejection — graft dysfunction without a convincing infectious source may raise concern, but infection and rejection can coexist; premature steroid treatment may worsen occult infection.
Medication toxicity — a temporal relationship or drug-level abnormality may be informative; missing toxicity can compound renal or neurologic injury.
Obstruction or vascular graft complication — abnormal graft imaging or reduced perfusion can discriminate; treating presumed infection alone may delay a time-sensitive intervention.
Routine community-acquired infection — familiar symptoms can occur, but transplant status changes pathogen risk; using inadequate empiric coverage can delay control.
Board Question
A kidney-transplant recipient on immunosuppression presents with hypotension and elevated lactate but no fever. What is the most appropriate immediate approach? -
AWithhold antibiotics until cultures identify a pathogen -
BTreat instability as possible sepsis, begin indicated resuscitation and empiric antibiotics, and involve the transplant team -
CStop all antirejection medicines immediately -
DGive high-dose steroids for presumed rejection before evaluating for infection
Reveal answer
Correct: B
Immunosuppression can blunt fever and other inflammatory signs; treat physiologic instability promptly while investigating infection and graft dysfunction in parallel. Antirejection therapy should not be abruptly changed without transplant-team input.
A broad reference for checking the transplanted organ, immunosuppressive regimen, and infection risks when a transplant recipient presents to the ED.
3 of 4
Hemophilia
Bleeding can be occult, delayed, and catastrophic—especially intracranial, airway, retroperitoneal, or compartment bleeding. Replace the missing factor...
Also known asfactor VIII deficiency · factor IX deficiency · Christmas disease · hemophilia A · hemophilia B
0:00 / –:––AI‑generated audio
The Case
A 24-year-old man arrives holding a towel against the back of his head, where a small patch of blood has dried into his hair. He says he slipped on wet stairs and struck the floor, then developed a worsening headache on the drive in. He is alert, but his answers are slower than his friend expects. The team is deciding what must happen before the scan.
Before You Read
What is the first time-critical action after significant trauma in a patient with hemophilia?
Which bleeding sites are immediately life-threatening even without visible blood?
When is desmopressin appropriate—and when must it not delay factor?
Why It Matters
Bleeding can be occult, delayed, and catastrophic—especially intracranial, airway, retroperitoneal, or compartment bleeding. Replace the missing factor promptly when serious bleeding is suspected; diagnostic imaging should not create a treatment delay.
When to Think of It
Consider hemophilia in a patient with known disease or unexplained deep-tissue, joint, mucosal, or post-traumatic bleeding. Ask type (A or B), severity, inhibitor history, factor product, and whether the patient uses emicizumab; obtain their treatment card or contact their hemophilia center when possible.
Sick or Not Sick
Is there suspected life-, limb-, or organ-threatening bleeding? Head injury, neurologic change, major trauma, airway/neck bleeding, abdominal or flank pain, compartment signs, or hemodynamic instability triggers immediate factor replacement and emergency evaluation.
The First Fifteen Minutes
If major bleeding or significant head trauma is suspected in hemophilia A: give factor VIII 50 IU/kg IV as an initial dose, targeting near-normal factor activity; it replaces deficient clotting factor. Dose using the known product and hematology plan when available.
If major bleeding is suspected in hemophilia B: give factor IX about 100 IU/kg IV as an initial dose when a near-normal level is needed; product recovery varies, so use the patient’s plan or consult hematology urgently.
If mild hemophilia A is confirmed and the patient is a known responder with minor bleeding: give desmopressin 0.3 mcg/kg IV (maximum 20 mcg) over 20–30 minutes; it releases endogenous von Willebrand factor and factor VIII. It is not a substitute for factor in major bleeding.
For mucosal bleeding when appropriate: give tranexamic acid 1 g IV or 1–1.5 g orally; it stabilizes formed clot. Avoid in suspected upper urinary-tract bleeding because obstructing clots can form.
Stabilize airway and circulation, examine for compartment syndrome, obtain urgent imaging for head or torso trauma, and contact hematology. Do not wait for coagulation results or imaging before factor replacement for suspected major bleeding.
Definitive Care & Disposition
Admit for intracranial or other major bleeding, serious trauma, ongoing factor needs, neurovascular compromise, or uncertain follow-up; involve hematology and the relevant surgical service early. Continue factor replacement to the site-specific target and duration. A normal aPTT does not reliably exclude hemophilia in patients receiving emicizumab; coordinate assays with the hemophilia center. Avoid intramuscular injections and unnecessary invasive procedures.
How This One Kills
Delaying factor replacement until CT confirms intracranial hemorrhage can allow bleeding to expand; in hemophilia, treat serious suspected bleeding before confirmation.
The Atypical Presentation
In young children, nonverbal patients, or people with milder disease, the first clue may be irritability, refusal to use a limb, unexplained bruising, or delayed symptoms after a minor injury. A normal early exam or lack of external blood does not rule out serious internal bleeding. Ask directly about inherited bleeding disorders, prior factor use, inhibitors, and hemophilia medications; compare with the patient’s baseline and treat serious suspected bleeding early.
Back to Our Patient
Back to our 24-year-old with the blood-matted hair and worsening headache: known hemophilia A plus head trauma makes intracranial bleeding an immediate concern, even though he is alert. He receives factor VIII 50 IU/kg IV before imaging, with hematology contacted; urgent head CT shows no intracranial hemorrhage, and serial neurologic examinations remain stable. He is observed with the hemophilia team’s guidance and discharged only after a safe plan for continued monitoring and return precautions is established.
Patient Presentation to Attending
“This is a 24-year-old man with known hemophilia A who struck the back of his head in a fall and has a worsening headache with slower-than-usual responses. He is alert and has no reported loss of consciousness, vomiting, seizure, or focal weakness. There is a small occipital scalp wound; his neurologic exam is currently nonfocal. Because head trauma in hemophilia risks occult intracranial bleeding, he received factor VIII 50 IU/kg IV before imaging. CT shows no hemorrhage, and serial examinations remain stable. I recommend hematology-directed observation and discharge only if symptoms remain stable and follow-up is reliable.”
Study Directive
From memory, calculate a factor VIII dose for a 70-kg adult needing a 100% factor rise.
Rehearse the first-minute checklist for head trauma in hemophilia: factor type, inhibitor status, immediate factor, imaging, hematology.
Review your local pathway for hemophilia patients taking emicizumab, including which assays are reliable.
Key Medications
Factor VIII: for major bleeding, initial dose commonly 50 IU/kg IV to raise activity close to 100%; calculated dose in IU ≈ weight (kg) × desired rise in factor VIII (%) × 0.5.
Factor IX: a near-normal initial target may require about 100 IU/kg IV, but recovery varies by product and patient; verify the treatment plan or dosing reference.
Desmopressin:0.3 mcg/kg IV over 20–30 minutes (maximum 20 mcg) for minor bleeding in known responsive mild hemophilia A; monitor fluid intake and sodium with repeat dosing.
Tranexamic acid:1 g IV or 1–1.5 g orally for suitable mucosal bleeding; avoid with suspected upper urinary-tract bleeding.
Pediatric factor dosing is weight-based; factor targets and repeat dosing depend on the bleeding site, product, and inhibitor status. Check hematology or institutional guidance when uncertain.
High-Yield Pearls
Hemophilia bleeding is often delayed; worsening pain or function after an injury matters even when the first examination is reassuring.
In a patient taking emicizumab, aPTT-based testing can mislead; contact the hemophilia center about appropriate assays.
Do not aspirate a suspected hemarthrosis or inject intramuscularly before coordinating hemostatic coverage.
The Mimics
von Willebrand disease — mucocutaneous bleeding is more typical than recurrent deep-joint bleeding; confusing the disorders can lead to ineffective factor choice.
Septic arthritis — fever or systemic illness and joint aspiration findings may discriminate, but aspiration without hemostatic planning can cause significant bleeding.
Compartment syndrome — escalating pain, pain with passive stretch, and tense compartments are key clues; attributing these findings to a routine muscle bleed risks limb loss.
Anticoagulant-associated bleeding — medication exposure and drug-specific testing help distinguish it; reversal differs, and factor replacement alone may be inadequate.
Board Question
A patient with severe hemophilia A presents after head trauma with headache but a nonfocal neurologic examination. What is the best next step? -
AWait for CT confirmation before giving factor -
BGive factor VIII promptly, then obtain urgent head imaging -
CGive desmopressin as definitive therapy for severe hemophilia -
DDischarge if the initial neurologic examination is normal
Reveal answer
Correct: B
Suspected intracranial bleeding is life-threatening; replace factor promptly and do not wait for imaging confirmation. Desmopressin is for selected mild, responsive hemophilia A—not severe disease or major bleeding.
Guidance on factor replacement and management of acute bleeding helps ED clinicians treat suspected serious hemorrhage without delaying for confirmatory testing.
Alteplase can cause rapidly expanding, life-threatening bleeding, especially intracranial hemorrhage. Stop the drug and restore hemostasis promptly; delays...
Also known astPA reversal · thrombolytic reversal · fibrinolytic reversal · Activase reversal
A 71-year-old man has been speaking more clearly since the infusion began, and his daughter is starting to relax. Then he grips the bed rail, says the room is splitting in two, and vomits. The blood-pressure cuff cycles again as his level of alertness slips. The team must decide whether the infusion can continue.
Before You Read
What is the first move when serious bleeding is suspected during alteplase?
Which blood product reverses alteplase-associated fibrinolysis?
What laboratory target guides repeat reversal treatment?
Why It Matters
Alteplase can cause rapidly expanding, life-threatening bleeding, especially intracranial hemorrhage. Stop the drug and restore hemostasis promptly; delays while waiting for laboratory confirmation can cost the patient their life.
When to Think of It
Suspect symptomatic intracranial hemorrhage in a patient receiving or recently treated with alteplase who develops sudden headache, vomiting, neurologic decline, acute hypertension, or reduced consciousness. Also consider serious systemic bleeding, including gastrointestinal or retroperitoneal hemorrhage.
Sick or Not Sick
Is there suspected life-threatening bleeding? If yes, stop the alteplase infusion immediately and begin hemorrhage evaluation and reversal; do not wait for CT or coagulation results to start the reversal pathway.
The First Fifteen Minutes
If serious bleeding is suspected during an alteplase infusion: stop the infusion immediately; ongoing fibrinolysis can worsen bleeding.
If symptomatic intracranial hemorrhage or other life-threatening bleeding is suspected: give cryoprecipitate 10 units IV; it replenishes fibrinogen consumed by fibrinolysis. Send fibrinogen urgently and target >150 mg/dL; repeat cryoprecipitate if the level remains below target, following local protocol.
If cryoprecipitate is unavailable or cannot be given promptly: give tranexamic acid 10–15 mg/kg IV (maximum 1 g) over about 10 minutes; it inhibits fibrinolysis while definitive blood-product reversal is arranged. Dosing protocols vary—check institutional guidance.
If intracranial hemorrhage is confirmed and blood pressure requires treatment: give nicardipine 5 mg/hour IV, increasing by 2.5 mg/hour every 5–15 minutes to a maximum 15 mg/hour, or labetalol 10–20 mg IV over 1–2 minutes, with one repeat dose if needed. Controlled blood-pressure reduction may limit hematoma expansion; individualize the target with the stroke/neurocritical-care team.
Obtain emergent noncontrast head CT, CBC, fibrinogen, PT/INR, aPTT, type and cross, and neurosurgical/neurocritical-care consultation. Do not delay reversal for imaging when serious bleeding is suspected.
Definitive Care & Disposition
Admit confirmed symptomatic intracranial hemorrhage to a neurocritical-care or ICU setting; involve stroke neurology, neurosurgery, and transfusion medicine. Recheck fibrinogen after replacement and give additional cryoprecipitate if it remains below target. Manage blood pressure, intracranial pressure, and any need for procedural source control with specialists. Do not use routine anticoagulant reversal agents as substitutes for fibrinogen replacement.
How This One Kills
Waiting for CT confirmation or a fibrinogen result before stopping alteplase and starting reversal can allow an intracranial hematoma to expand during ongoing fibrinolysis.
The Atypical Presentation
An older patient may have only new confusion, reduced responsiveness, or a modest change in headache, while sedation or an existing stroke obscures neurologic worsening. Bleeding can also occur after the infusion has ended. Establish the exact alteplase timing, compare with the last documented neurologic examination, inspect for other bleeding, and treat abrupt deterioration as a time-critical hemorrhage until excluded.
Back to Our Patient
Back to our 71-year-old whose speech had improved before the sudden double vision and vomiting: the abrupt decline during alteplase makes serious intracranial bleeding the key risk. The infusion is stopped immediately; blood is sent for fibrinogen and other studies, cryoprecipitate 10 units IV is given, and urgent CT shows a new intracranial hemorrhage. His blood pressure is treated with titrated nicardipine, fibrinogen is rechecked and corrected to target, and he is admitted to neurocritical care with stroke and neurosurgical teams involved.
Patient Presentation to Attending
“This is a 71-year-old man receiving alteplase for acute ischemic stroke who developed sudden diplopia, vomiting, and declining alertness during the infusion. His speech had initially improved; he now has an abrupt neurologic deterioration without reported seizure or new trauma. He is less responsive than on his last documented examination, and his blood pressure is elevated. I’m concerned for symptomatic intracranial hemorrhage related to alteplase. The infusion is stopped, cryoprecipitate has been started, fibrinogen and blood-bank studies are pending, and emergent CT confirms a new hemorrhage. He needs neurocritical-care admission, fibrinogen-guided replacement, blood-pressure control, and immediate stroke/neurosurgical involvement.”
Study Directive
Recite the alteplase-bleeding sequence from memory: stop infusion, send fibrinogen, start reversal, obtain imaging, call specialists.
Review your local cryoprecipitate ordering and fibrinogen-recheck workflow; identify the after-hours blood-bank contact.
Compare alteplase reversal with anticoagulant reversal: name the target being replaced or corrected in each case.
Key Medications
Cryoprecipitate:10 units IV initially for suspected life-threatening alteplase-associated bleeding; recheck fibrinogen and repeat to a goal >150 mg/dL. Product content and local protocols vary.
Tranexamic acid:10–15 mg/kg IV, maximum 1 g, if cryoprecipitate is unavailable or delayed; protocols vary, so check local guidance.
Nicardipine:5 mg/hour IV, increase by 2.5 mg/hour every 5–15 minutes, maximum 15 mg/hour.
Labetalol:10–20 mg IV over 1–2 minutes, repeat once if needed.
Pediatric use is uncommon and dosing should follow pediatric specialist/institutional protocols.
High-Yield Pearls
Normal PT/INR or aPTT does not rule out clinically important alteplase-associated fibrinolysis.
The practical reversal endpoint is fibrinogen recovery—generally above 150 mg/dL—not simply completion of a fixed cryoprecipitate dose.
A sudden exam change during thrombolysis is not “stroke evolution” until hemorrhage has been urgently assessed.
The Mimics
Post-stroke hemorrhagic transformation — repeat imaging distinguishes blood from recurrent ischemia; assuming ongoing ischemia can delay reversal of a bleed.
Cerebral edema or recurrent ischemia — imaging and the neurologic pattern help discriminate; unnecessary reversal can expose a patient to thrombosis.
Seizure or postictal state — witnessed convulsions or fluctuating recovery support it; mistaking hemorrhage for seizure can delay imaging and reversal.
Orolingual angioedema — tongue or lip swelling and airway symptoms, often without new focal deficits, point away from intracranial bleeding; confusing them may delay airway protection.
Board Question
A patient develops abrupt neurologic deterioration during an alteplase infusion. Intracranial hemorrhage is suspected. Which is the best immediate approach? -
AContinue alteplase until head CT confirms hemorrhage -
BStop alteplase and give cryoprecipitate while obtaining urgent imaging and fibrinogen -
CGive vitamin K and wait for the INR -
DGive platelets routinely before checking a CBC
Reveal answer
Correct: B
Stop the infusion and begin reversal for suspected life-threatening bleeding without waiting for CT or fibrinogen confirmation. Cryoprecipitate replaces fibrinogen; subsequent dosing is guided by repeat fibrinogen and local protocol.
For alteplase-associated intracranial hemorrhage, stop the infusion and urgently replace fibrinogen with cryoprecipitate; consider an antifibrinolytic if cryoprecipitate is unavailable.
Yesterday’s Differential
The daily puzzle — from editions past
A quick test of recall from prior editions. Commit to an answer before you check.
From yesterday's edition
EMS rolls in doing compressions. The monitor shows a chaotic irregular waveform without identifiable QRS complexes. What’s the diagnosis, and the first move?
Check your answer
Ventricular Fibrillation. Defibrillate, resume CPR immediately, follow ACLS shockable rhythm algorithm, and search for reversible causes during rhythm checks and after ROSC.
From the October 4 edition
Today, three days ago: Labetalol. What’s the adult ED dose, and the contraindication you’d most regret missing?
Check your answer
10–20 mg IV over 2 min; repeat or double every 10 min to effect per protocol, or infusion 0.5–2 mg/min. Pregnancy severe HTN regimens often use 20/40/80 mg stepwise dosing. Asthma/COPD with active bronchospasm, bradycardia, heart block, cardiogenic shock, decompensated heart failure, cocaine/stimulant toxicity caution depending on scenario.
From the September 27 edition
A patient develops sudden hypoxia and hypotension during delivery, followed by diffuse bleeding and laboratory evidence of DIC. Which is the best next step?
AWait for a serum test to confirm the diagnosis
BBegin supportive resuscitation and activate obstetric hemorrhage and critical-care teams
CStart anticoagulation for presumed pulmonary embolism
DGive corticosteroids as disease-specific therapy
Reveal answer
Correct · B
AFE is a clinical diagnosis, and care is immediate supportive resuscitation with coordinated obstetric, critical-care, and hemorrhage management. No confirmatory test or proven disease-specific drug should delay treatment.
Journal Watch
From the FOAMed wire
Notable posts and reviews from the last week, ranked by relevance to today’s lead and source trust.
Brain damage and death from ischemic encephalopathy is common after cardiac arrest. Animal studies and limited observational studies suggest that high oxygen exposure after ROSC may result in neuronal death. As such, it is hypothesized that limiting oxygen exposure (conservative oxygen) many attenuate reperfusion injury and improve outcomes. At present,...
Source
Critical Care Perspectives in Emergency Medicine
Published
2026-09-01
Host
Critical Care Perspectives in Emergency Medicine, Critical Care Perspectives in Emergency Medicine
EMCrit 435 – Procedural Sedation Part V I break down the new ACEP unscheduled procedural sedation guidelines, call out the absurd pretense surrounding 'deep sedation', and lay out where emergency sedation needs to go...
Critical Care Corner
Matched to today’s topics
A critical-care reference from LITFL’s Critical Care Compendium, tied to today’s differential.
In hemophilia, a prolonged aPTT with a normal PT points toward an intrinsic-pathway factor deficiency; a mixing study helps distinguish deficiency from an inhibitor.
OVERVIEW PROTHROMBIN TIME -> warfarin-> vitamin K deficiency-> liver disease-> DIC-> artefact: incorrect sampling or increased haematocrit (> 55%) ACTIVATED PARTIAL THROMBOPLASTIN TIME -> heparin-> DIC-> haemophilia-> liver disease THROMBIN TIME -> heparin-> DIC-> hypofibrinogenaemia-> fibrin degradation products FIBRINOGEN -> sepsis-> DIC FIBRIN DEGRADATION PRODUCTS (FDPs) APTT 50% NP -> lupus an
Pharmacology Corner
Two drugs for the shift
One antimicrobial and one other ED workhorse — selected daily, with sources and last-reviewed dates so every dose is cross-checkable.
Antimicrobial of the Day
Cefazolin
First-generation cephalosporin
Indication
MSSA and streptococcal skin/soft tissue infection, open fracture prophylaxis per trauma/orthopedic protocols, peri-procedural prophylaxis, and selected cellulitis cases without MRSA risk.
What’s your dose? — reveal dosing & cautions
ED Dose
2 g IV once/q8h; 3 g IV for patients ≥120 kg in many prophylaxis protocols. Open fracture prophylaxis commonly begins with 2 g IV as early as possible.
Renal Adjustment
Adjust interval after initial ED dose when CrCl < 50 mL/min; hemodialysis dosing depends on timing and local protocol.
Contraindications
Severe cephalosporin allergy; caution with immediate anaphylaxis history to beta-lactams.
Interactions
Warfarin effect may increase with prolonged therapy; probenecid increases beta-lactam levels.
Monitoring
Allergic reaction, renal function for repeat dosing, clinical response of cellulitis/wound infection.
ED Pearl
For clean open fractures, early cefazolin is more important than exotic coverage — give it quickly, document time, then tailor based on contamination pattern.
Suspected or confirmed ethylene glycol or methanol poisoning, especially with osmolar gap, metabolic acidosis, visual symptoms, renal injury, or credible exposure.
What’s your dose? — reveal dosing & cautions
ED Dose
15 mg/kg IV load, then 10 mg/kg IV q12h for 4 doses, then 15 mg/kg q12h until toxic alcohol level/clinical criteria resolved. Dose more frequently during hemodialysis per protocol.
Renal Adjustment
No renal adjustment, but hemodialysis removes fomepizole; increase frequency during dialysis.
Contraindications
Hypersensitivity to fomepizole/pyrazoles. In life-threatening toxic alcohol ingestion, contraindications are rare.
Interactions
Ethanol competes for alcohol dehydrogenase; avoid unnecessary coadministration unless directed by toxicology.
For educational use only. Verify dosing against the FDA label and your institution’s pharmacy resources before administering.
ECG of the Day
Conduction
Left Bundle Branch Block
A broad QRS with a dominant S wave in V1 and a broad monophasic R wave laterally is LBBB — and knowing what discordance is allowable is what lets you spot the infarct hiding inside it.
The Tracing
A 70-year-old woman with hypertension and aortic stenosis presents with chest pressure. Her vitals are stable. The 12-lead shows a wide QRS, clearly beyond 120 ms. In V1 there is a deep, dominant S wave with only a tiny initial R wave; in leads I, aVL, and V5-V6 there is a broad, notched, M-shaped R wave with no preceding Q waves. R-wave progression across the precordium is poor and the axis is leftward. In the lateral leads with the tall R waves you see some ST depression and T-wave inversion, while the right precordial leads with deep S waves carry a modest amount of ST elevation. You study the proportions of those ST shifts against the QRS.
QRS duration >=120 ms with a dominant S wave in V1 (rS or QS complex)
Broad, monophasic, often M-shaped/notched R wave in the lateral leads (I, aVL, V5-V6) with absence of Q waves there
Prolonged R-wave peak time >60 ms in V5-V6
Left axis deviation and poor R-wave progression across the precordium
Appropriate discordance — ST segment and T wave point opposite to the main QRS deflection
Pearls
Appropriate discordance is the rule: leads with deep S waves may show ST elevation that is allowable up to roughly 25% of the S-wave depth without meaning ischemia. Judge the ST shift as a proportion of the QRS, not in absolute millimeters.
LBBB rarely exists without underlying organic disease — aortic stenosis, ischemic heart disease, hypertension, dilated cardiomyopathy, and Lenegre-Lev degeneration are among the drivers, so its presence flags a diseased heart.
New LBBB with chest pain is no longer an automatic STEMI-equivalent; modern practice is to hunt for excessive discordance or concordant ST change rather than reflexively activating on the block alone.
Pitfalls
Any concordant ST change — ST shift in the same direction as the main QRS deflection — is concerning for ischemia and should not be dismissed as part of the block (apply Sgarbossa reasoning).
Right ventricular paced rhythms produce a nearly identical LBBB-like morphology; look for pacing spikes to tell them apart.
LVH can mimic LBBB with QRS widening and lateral ST depression / T-wave inversion — don't over-call a bundle branch block on voltage and repolarization changes alone.
At the Bedside
In a chest-pain patient with LBBB, don't stop at the block — measure ST shifts against QRS proportions and apply Sgarbossa/excessive-discordance criteria; concordant ST change or excessive discordance drives emergent cath lab activation, while an old LBBB with only appropriate discordance directs you to serial troponins and an alternative workup.
For educational use only. Verify ECG interpretation against the LITFL entry and your institution’s practice before clinical decision-making.
Case of the Day
From the lead · Adverse Effects of Immune Checkpoint Inhibitors
Self-Examination
Test Your Understanding
A patient receiving checkpoint inhibitor therapy presents with hypotension, hyponatremia, and hypoglycemia. Adrenal crisis is suspected. Which is the best next step? -
AWait for the cortisol result before treating -
BGive hydrocortisone 100 mg IV after drawing cortisol/ACTH if this does not delay treatment -
CGive methylprednisolone 1 mg/kg only after pituitary MRI -
DDischarge if blood pressure improves after oral fluids
Reveal answer
Correct answer · B
Suspected adrenal crisis requires prompt glucocorticoid replacement; cortisol and ACTH can be drawn first only if doing so does not delay treatment. Imaging and definitive endocrine workup follow stabilization.
Study Pace4 topics today; Issue 85 of 94 — Hematology and Oncology (Week 47)Deadline · June 1, 2026